SRPT Sarepta Therapeutics Inc.

Sarepta Therapeutics to Announce Second Quarter 2022 Financial Results and Recent Corporate Developments on August 2, 2022

Sarepta Therapeutics to Announce Second Quarter 2022 Financial Results and Recent Corporate Developments on August 2, 2022

CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2022 financial results after the Nasdaq Global Market closes on Tuesday, August 2, 2022. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its second quarter 2022 financial results and to provide a corporate update.

The event will be webcast live under the investor relations section of Sarepta's website at and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using . After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.

About Sarepta Therapeutics

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit  or follow us on , , and .

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website at . We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Investor Contact:

Ian Estepan, 617-274-4052

Media Contact:

Tracy Sorrentino, 617-301-8566



EN
26/07/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sarepta Therapeutics Inc.

Sarepta Therapeutics Inc: 1 director

A director at Sarepta Therapeutics Inc bought 37,038 shares at 133.801USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch